<?xml version="1.0" encoding="UTF-8"?>
<p id="Par26">The primary endpoint of the study was to determine the effect of FLU-v on reducing the incidence of MMID, defined as detectable viral shedding by an FDA approved clinical testing method for influenza plus at least one clinical symptom/sign of influenza at any time during the inpatient portion of the study. Secondary outcome measures included incidence of viral shedding, incidence of influenza symptoms, incidence of two or more influenza symptoms, total quantity of symptoms, quantity of viral shedding, symptom severity, and safety during the inpatient portion of the study.</p>
